Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia.
- Authors
- Maehara, Shunsuke; Hikichi, Hirohiko; Satow, Akio; Okuda, Shoki; Ohta, Hisashi
- Year
- 2008
- Journal
- Pharmacology, biochemistry, and behavior
- PMID
- 18651995
- DOI
- 10.1016/j.pbb.2008.06.023
Pharmacological evidence has implicated cholinergic dysfunction in the manifestation of psychotic symptoms. The purpose of the present study was to clarify the roles of muscarinic and nicotinic receptors in several animal models of schizophrenia. A muscarinic receptor agonist, oxotremorine (0.03-0.3 mg/kg), reversed hyperlocomotion in mice and disruption of prepulse inhibition (PPI) caused by methamphetamine in rats, similar to a typical antipsychotic drug, haloperidol (0.1-0.3 mg/kg). In addition to modulating hyperdopaminergic function, oxotremorine as well as clozapine (3-10 mg/kg) reversed the disruption of PPI caused by ketamine, an N-methyl-D-aspartate antagonist in rats, which mimics the clinical symptoms of schizophrenia. One of the spontaneous mouse models, DBA/2J exhibited lower PPI than C57BL/6J. Oxotremorine (0.03-0.06 mg/kg) increased PPI in DBA/2J but not C57BL/6J. On the other hand, a nicotinic receptor agonist, nicotine (0.06-0.6 mg/kg), exhibited no effects on the four animal models of symptoms of schizophrenia we tested. These findings suggest that muscarinic receptors play important roles in animal models to examine sensory gating which is known to be disrupted in schizophrenic patients, and hence activation of muscarinic receptors may provide an alternative approach for the treatment of psychotic symptoms in addition to classical antipsychotics.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | 2019 | 31740666 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets. | Yates JR | β | 2024 | β |
| Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms. | Carvalho C et al. | β | 2022 | β |
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | Cheng Z et al. | β | 2019 | β |
| Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. | Teal LB et al. | β | 2019 | β |
| Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. | Shin EJ et al. | β | 2017 | β |
| Sigma Receptors and Substance Use Disorders. | Sabino V et al. | β | 2017 | β |
| State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. | Gould RW et al. | β | 2016 | β |
| Scopolamine and amphetamine produce similar decision-making deficits on a rat gambling task via independent pathways. | Silveira MM et al. | β | 2015 | β |
| The murine serotonin syndrome - evaluation of responses to 5-HT-enhancing drugs in NMRI mice. | Haberzettl R et al. | β | 2015 | β |
| Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats. | FijaΕ K et al. | β | 2014 | β |
| The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. | Huang M et al. | β | 2014 | β |
| Role of convergent activation of glutamatergic and dopaminergic systems in the nucleus accumbens in the development of methamphetamine psychosis and dependence. | Miyazaki M et al. | β | 2013 | β |
| Role of murine models in psychiatric illness drug discovery: a dimensional view. | Hoffman KL | β | 2013 | β |
| The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder. | Yankelevitch-Yahav R et al. | β | 2013 | β |
| Methamphetamine-associated psychosis. | Grant KM et al. | β | 2012 | β |
| Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. | D'Souza MS et al. | β | 2012 | β |
| Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats--possible involvement of activation of M(1) muscarinic receptors. | Maehara S et al. | β | 2011 | β |
| Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice-Possible involvement of muscarinic receptors. | Maehara S et al. | β | 2011 | β |
| Involvement of the cholinergic system in conditioning and perceptual memory. | Robinson L et al. | β | 2011 | β |
| Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. | Thomsen M et al. | β | 2010 | β |
| Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice. | Hikichi H et al. | β | 2010 | β |
| Repeated methamphetamine treatment increases expression of TRPV1 mRNA in the frontal cortex but not in the striatum or hippocampus of mice. | Tian YH et al. | β | 2010 | β |
| A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. | Buccafusco JJ et al. | β | 2009 | β |
| Effects of some antipsychotics and a benzodiazepine hypnotic on the sleep-wake pattern in an animal model of schizophrenia. | Ishida T et al. | β | 2009 | β |
| Methamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotonergic toxicity. | Bortolato M et al. | β | 2009 | β |
| Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. | Karasinska JM et al. | β | 2009 | β |